Navigation Links
Aviir Signs Distribution and Expansion Pact Covering 19 Middle Eastern and North African Countries
Date:2/19/2013

IRVINE, Calif., Feb. 19, 2013 /PRNewswire/ -- Aviir Inc., a biotechnology company dedicated to the prevention of cardiovascular disease through innovative laboratory tests, announced that it has signed an agreement with Partners & Partners (P&P) under which P&P will form the sole distributorship of Aviir testing products and technologies in 19 Middle Eastern and North African Countries. Through its affiliate, Qatar Heart Laboratory Holding, P&P intends to roll out, country-by-country, a network that will distribute and promote Aviir tests, including the Aviir MIRISK VP™ Assessment.  The agreement follows the recently announced $10 million financing tranche for Aviir, which included participation by the company's current investor group, along with P&P.

The Aviir MIRISK VP™ was developed out of basic research at the Stanford University School of Medicine and can assess the risk of a patient having a major coronary event within the coming 5 years.

Aviir CEO Douglas Harrington , MD, commented, "The Middle East has seen a steep rise in both obesity and diabetes, resulting in a parallel increase in cardiac disease and its complications in those societies."

"In the past decade, diabetic prevalence has reached more than 20 percent and obesity rates exceed 35 percent of the population in some Middle Eastern Countries," said Dr. Harrington. "The governments and health care authorities in that region are now taking a proactive approach to finding and implementing solutions to those trends.  We are looking forward to working with our new distributor to penetrate these hard-to-access markets and to providing an important new tool in the fight against catastrophic cardiac events."

Under the agreement, P&P will have the exclusive rights to set up diagnostic laboratories across the region, including Qatar
'/>"/>

SOURCE Aviir Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Aviir Diagnostics Laboratory in Collaboration with Cause;ology Sponsors "Storyland," a Red Carpet Charity Extravaganza in Hollywood
2. Aviir Laboratories Announce National Agreement With MultiPlan
3. Aviir Laboratories Announce National Agreement with Three Rivers Provider Network
4. Aviir Laboratories Announce National Agreement with Stratose
5. Aviir Diagnostic Laboratories Secures $8 Million In Funding From Silicon Valley Bank
6. Aviir, Inc.s CEO Dr. Douglas Harrington Delivered The Facts Surrounding Heart Disease At The Los Angeles Ultimate Womens Expo
7. Aviir Sponsors Eco Hideaway 2013 Music Artist Stage At The Chateaux In Park City, Utah To Benefit Heart Disease
8. Bacterin Signs Distribution Agreement with Jeil for LeForte Craniomaxillofacial System
9. Roche Signs Agreement with PTC Therapeutics to Advance Treatment for Spinal Muscular Atrophy (SMA)
10. BioRestorative Therapies Signs Material Manufacturing Agreement With University of Utah
11. The European Union Signs Grant Contract to Fund a 2 Million Euro Biotechnology Research Project Led by Hadassah College Jerusalem
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... 20, 2014 The report, ... Oligos, Enzymes, Cloning kits), Technology (Bioinformatics, Nanotechnology, ... Pharmaceuticals, Biomaterials, Bioremediation) - Global Forecast to ... drivers, threats, opportunities, and challenges. , Browse ... spread through 185 pages and in-depth TOC ...
(Date:11/21/2014)... Why did Stephen Hawking become so famous? ... recognizable? Why have they become icons to rival film ... Ratcliffe seeks out the answers to those questions, and ... with science. In " Stephen Hawking Smoked My Socks ... Ratcliffe puts it plainly: , “It is profoundly ...
(Date:11/21/2014)... Polaris Group announced today that the ... 1 trial of ADI-PEG 20 in combination with ... pleural mesothelioma (MPM) and non-squamous non-small cell lung ... ADI-PEG 20, both as monotherapy and in combination ... other indications, including breast cancer, melanomas, ovarian cancer, ...
(Date:11/21/2014)... - BIOREM Inc. (TSXV: BRM) ("Biorem" or "the Company") today announced results ... 2014.  Biorem,s complete 2014 third quarter financial statements and MD&A have ... ended September 30, , Nine-months ended September ... 2014 , 2013 , 2014 , ... , 6,715 , 14,476 Gross profit , ...
Breaking Biology Technology:Synthetic Biology Market Expected to Reach $5,630.4 Million in 2018 - New Report by MarketsandMarkets 2Synthetic Biology Market Expected to Reach $5,630.4 Million in 2018 - New Report by MarketsandMarkets 3Synthetic Biology Market Expected to Reach $5,630.4 Million in 2018 - New Report by MarketsandMarkets 4“Stephen Hawking Smoked My Socks” Sparks Controversy in Science World 2“Stephen Hawking Smoked My Socks” Sparks Controversy in Science World 3“Stephen Hawking Smoked My Socks” Sparks Controversy in Science World 4Polaris Group Announces Treatment of First Patient in Phase 1 Study of ADI-PEG 20 plus Pemetrexed and Cisplatin in Malignant Pleural Mesothelioma And Non-Squamous Non-Small Cell Lung Carcinoma 2Biorem Reports Third Quarter Results 2Biorem Reports Third Quarter Results 3
... of siRNAs targeting , key ... cells. To identify genes involved in a given cellular process, , ... distinct response profiles such as ... Inc., who pioneered the field of High Content , ...
... , Up to 50X more activity and 350% greater ... Removes trace quantities of , DNA ... RNase-free and recombinant in , ... lower in RNase activity than bovine pancreas , ...
... ... fastest, easiest, and most consistent method for PAGE purification of small , ... which was designed for the visualization of small nucleic acids, the flashPAGE ... of RNA , and DNA. , ...
Cached Biology Technology:Using Validated siRNAs in Functional Genomic Assays 2Using Validated siRNAs in Functional Genomic Assays 3TURBO DNase: Hyperactive, Salt Tolerant DNase 2TURBO DNase: Hyperactive, Salt Tolerant DNase 3TURBO DNase: Hyperactive, Salt Tolerant DNase 4TURBO DNase: Hyperactive, Salt Tolerant DNase 5Ultra-Fast Purification of Small Nucleic Acids 2Ultra-Fast Purification of Small Nucleic Acids 3Ultra-Fast Purification of Small Nucleic Acids 4Ultra-Fast Purification of Small Nucleic Acids 5
(Date:11/4/2014)... (Nov. 4, 2014) – A majority of Madagascar,s 101 ... could have serious consequences for the rainforests they call ... the positive impacts lemurs can have on rainforest tree ... disappearance could have on the region,s rich biodiversity. , ... fruits eaten by lemurs. Lemurs in turn disperse ...
(Date:11/3/2014)... DUBLIN , Nov. 3, 2014 Research ... report "Cell Therapy - Technologies, Markets and Companies" ... evaluates cell therapy technologies and methods, which have already started ... Hematopoietic stem cell transplantation is replacing the old fashioned bone ... described. Cell therapy is bound to become a part of ...
(Date:11/3/2014)... 3, 2014  NeuroSigma ® , Inc. (NeuroSigma), ... company focused on commercialization of its non-invasive ... treatment of neurological and neuropsychiatric disorders, announced today ... issued a Notice of Allowance for Mexican Patent ... by NeuroSigma and the Regents of the University ...
Breaking Biology News(10 mins):Gardeners of Madagascar rainforest at risk 2Gardeners of Madagascar rainforest at risk 3Global Cell Therapy - Technologies, Markets and Companies: 2014 Report 2Global Cell Therapy - Technologies, Markets and Companies: 2014 Report 3NeuroSigma Receives Notice of Allowance from the Mexican Institute of Industrial Property Covering Subcutaneous Trigeminal Nerve Stimulation (sTNS) 2NeuroSigma Receives Notice of Allowance from the Mexican Institute of Industrial Property Covering Subcutaneous Trigeminal Nerve Stimulation (sTNS) 3
... unusual symbiosis between tiny single-celled algae and highly specialized ... ecosystems, fertilizing the oceans by taking nitrogen from the ... organisms can use. Details of the symbiosis, ... , emerged from the investigation of a mysterious nitrogen-fixing ...
... development of new biocomposites based on the transformation ... for the construction sector. These innovative materials will ... BIocomposiTEs), a European Commission FP7 collaborative project co-participated ... (FI), EMPA (CH), EXERGY (UK), VERTECH (FR), ...
... pregnant makes a huge difference in the health of her ... ate before pregnancy might be important too. According to a ... Journal , what a group of female mice atebefore ... her offspring. These DNA alterations, called "epigenetic" changes, drastically affected ...
Cached Biology News:Unusual symbiosis discovered in marine microorganisms 2Unusual symbiosis discovered in marine microorganisms 3Unusual symbiosis discovered in marine microorganisms 4TECNALIA leads research to develop new biocomposites based on wheat straw and recycled paper 2A mother’s nutrition--before pregnancy--may alter the function of her children’s genes 2
Mouse monoclonal [TONI-1] to Angiotensin II Type 1 Receptor (rating: ****) ( Abpromise for all tested applications). entrezGeneID: 185 SwissProtID: P30556...
1/4" to 1/8" Adapter for Reflectance Probe Holder...
... Glucagon-like peptide-1(7-36) amide (GLP-1), C-terminal reactive. ... shows <0.1% cross reactivity with the ... other related peptides such as hGLP-2, ... mammalian species. GLP-1 is identical in ...
Human/Mouse/Rat AMPK beta 1 Affinity Purified Polyclonal Ab...
Biology Products: